http://qz.com/357728
For years, drug makers have feared the onslaught of competition from “biosimilars,” the generic version of drugs that are made by living organisms. That moment came last week when the FDA approved Novartis’s Zarxio, a near copy of Amgen’s blood cancer drug Neupogen and the first biosimilar in the US.
Opens the door for biological replacements for the traditional chemical pharmaceuticals at a much cheaper cost, and with only short patent life in the US. Potential for massive savings in healthcare, and only possible through Obamacare, which eliminated the legal blockade against them.